Small-Cap Stocks to Watch — April 2026
Five small-cap stocks with the largest fundamental score gains this week. Data-driven picks for April 2026. Try free for 30 days.
Every week, dozens of small-cap stocks experience meaningful fundamental shifts — earnings reports, cash raises, debt paydowns, or insider transactions that move their scores by 5+ points. These are the small-cap stocks to watch heading into April 2026: five names where underlying fundamentals changed materially in the past seven days, filtered through our scoring model and ranked by score improvement.
These aren't buy recommendations. They're data signals worth investigating. Use our screener to dig deeper into any name on this list, or read how our scoring methodology works before drawing conclusions.
What "Score Change" Actually Measures
Before reviewing this week's movers, a note on methodology. Our fundamental score runs 0–100 and draws on eight weighted factors: revenue growth, gross margin, cash runway, dilution, insider activity, valuation, debt load, and profitability trend. A 5-point weekly move is significant — it means at least one of those inputs shifted in a way the model treated as material.
Score changes are not the same as price momentum. A stock can score higher this week while the price falls, or vice versa. What the score captures is the quality and trajectory of the underlying business — not short-term sentiment.
For a deeper explanation of how each metric feeds the model, see our guide to 8 fundamental metrics every small-cap investor should track.
This Week's Movers
1. Revolution Medicines (RVMD) — Score: 62/100 (+8 pts)
| Metric | Previous | Current | Change |
|---|---|---|---|
| Cash Runway | 22 months | 34 months | +12 months |
| Revenue Growth | +45% | +68% | +23pp |
| Score | 54 | 62 | +8 |
What happened: RVMD completed a $350M equity offering and reported accelerating revenue from its RAS-targeted oncology pipeline. The cash infusion extends runway by 12 months, while clinical progress drove the revenue growth improvement from 45% to 68%.
Why it matters: Extended runway combined with accelerating growth is the most constructive fundamental combination in small-cap biotech. Both inputs moved in the right direction in the same reporting period — that's uncommon. Investors can now model a lower probability of a near-term dilutive financing event.
The trade-off: The $350M offering did increase share count. Dilution will be reflected as a partial score headwind next quarter. New investors are buying at a higher per-share cost basis than the offering price. According to SEC EDGAR filings, the offering was priced at a modest discount to the 30-day VWAP — standard for this size deal, but worth factoring into your position sizing.
What to watch: Next clinical readout timing. If the RAS program produces Phase 2 data while runway remains above 24 months, the score could hold or improve.
2. Goosehead Insurance (GSHD) — Score: 75/100 (+7 pts)
| Metric | Previous | Current | Change |
|---|---|---|---|
| Revenue Growth | +18% | +29% | +11pp |
| Gross Margin | 68% | 74% | +6pp |
| Score | 68 | 75 | +7 |
What happened: GSHD posted a strong Q1 preview showing accelerating premium growth and improving unit economics. The franchise model is scaling efficiently — new agency signings are up 35% year-over-year, driving both top-line acceleration and margin expansion.
Why it matters: Insurance distribution is typically a low-growth, margin-compressed category. GSHD is demonstrating that a tech-enabled franchise model can deliver revenue growth in the high twenties while simultaneously expanding gross margin by six points. Both conditions holding at the same time is the hallmark of a business with pricing power and operating leverage.
The trade-off: Valuation at 7.8x trailing sales is high for an insurance business, even a technology-enabled one. Growth deceleration — whether from market saturation or a harder P&C pricing environment — would compress the multiple quickly. The score reflects fundamentals, not valuation adequacy.
What to watch: Franchise renewal rates and policy retention. Those two metrics will determine whether the margin expansion is structural or one-time.
3. Treace Medical Concepts (TMCI) — Score: 58/100 (+6 pts)
| Metric | Previous | Current | Change |
|---|---|---|---|
| Revenue Growth | +12% | +22% | +10pp |
| Cash Runway | 14 months | 20 months | +6 months |
| Score | 52 | 58 | +6 |
What happened: TMCI reported better-than-expected Q4 results. Lapiplasty procedure volume re-accelerated, and the company reduced quarterly cash burn without a new financing event — which is the more meaningful signal here. Extending runway by six months organically means the business is consuming less capital, not borrowing more time.
Why it matters: Revenue re-acceleration from 12% to 22% at a med-tech company signals increasing surgeon adoption. Surgeon adoption curves in med-tech tend to be sticky — once a surgeon learns the procedure, repeat volume compounds. This is a leading indicator of sustained growth, not a one-quarter anomaly.
The trade-off: TMCI is still pre-profit with 20 months of runway. If growth doesn't translate to cash flow breakeven by mid-2027, the company will face financing decisions that could be dilutive. The 58 score reflects that constraint — the business is improving, but not yet self-funding.
What to watch: Path to cash flow breakeven. Every quarter of organic runway extension without new equity reduces the dilution risk embedded in the score.
4. Aehr Test Systems (AEHR) — Score: 66/100 (+9 pts)
| Metric | Previous | Current | Change |
|---|---|---|---|
| Revenue Growth | -12% | +18% | +30pp |
| P/S Ratio | 4.2x | 3.1x | -1.1x |
| Score | 57 | 66 | +9 |
What happened: AEHR's strategic pivot from silicon carbide (SiC) testing to gallium nitride (GaN) testing is gaining measurable traction. The company reported its first quarter of revenue growth in three quarters, driven by new GaN customer wins. The revenue swing — from -12% to +18% — is the largest single-quarter improvement in this week's watchlist.
Why it matters: Semiconductor test equipment demand is lumpy, but the underlying dynamic here is a platform transition. SiC testing demand slowed as EV adoption timelines stretched. GaN is the next-generation power semiconductor for data center and consumer electronics applications — a larger and faster-growing addressable market. If the customer wins announced this quarter translate to recurring tool utilization, the revenue recovery could have more duration than a typical equipment refresh cycle.
The trade-off: Semiconductor test equipment revenue depends on design wins converting to production orders. A single large customer win can create the appearance of recovery that doesn't persist. Revenue quality over the next two quarters will clarify whether this is a trend or a one-time event.
What to watch: Customer concentration in Q1 GaN revenue. If two or more distinct customers drove the recovery, the diversification signals something durable. If it's one customer, the risk profile is different.
5. monday.com (MNDY) — Score: 72/100 (+5 pts)
| Metric | Previous | Current | Change |
|---|---|---|---|
| Revenue Growth | +28% | +34% | +6pp |
| Rule of 40 | 38 | 48 | +10 |
| Score | 67 | 72 | +5 |
What happened: MNDY raised FY2026 guidance, citing strong enterprise adoption and improving free cash flow margins. The Rule of 40 score moved from 38 to 48 — a ten-point improvement in a single quarter. Crossing 40 is not just a numerical milestone; it signals that growth and profitability are compounding together rather than trading off.
Why it matters: SaaS companies that sustain a Rule of 40 score above 40 historically trade at meaningfully higher revenue multiples than those that don't. Investopedia's Rule of 40 definition and the broader SaaS investment community have documented this extensively — the threshold separates businesses that are scaling efficiently from those that are buying growth at the expense of margin. MNDY is now on the right side of that line.
The trade-off: monday.com is at the upper end of the small-cap range by market capitalization. It may transition to mid-cap classification during 2026, which would shift the institutional ownership profile and reduce small-cap fund exposure. That's a positive development for the underlying business but could create a technical selling period as index weights rebalance.
What to watch: Enterprise net revenue retention. If NRR holds above 110% as the company scales, the SaaS expansion flywheel is intact.
How to Interpret Score Changes in Context
A stock with a high score is not necessarily a better investment than one with a lower score. Context matters:
- A stock moving from 52 to 58 (like TMCI) is showing early-stage improvement in a business that carries meaningful risk. The score change is the signal; the absolute score is the risk calibration.
- A stock at 75 (like GSHD) is demonstrating stable, high-quality fundamentals with less distress risk — but potentially with less upside from further score improvement.
- A stock with a large swing (like AEHR, +9) may be recovering from a low base. Check whether the fundamentals that drove the decline have actually reversed, or whether a single data point is masking a still-fragile business.
For a framework on how to sequence these signals into a watchlist workflow, see our guide to finding undervalued small-cap stocks and our running coverage of the best small-cap stocks for Q2 2026.
Sector Patterns This Week
This week's five movers span five different sectors: biotech, insurance, med-tech, semiconductors, and SaaS. That breadth is unusual — most weeks, score improvements cluster in one or two sectors responding to shared macro inputs like interest rate guidance, earnings season cadence, or sector-specific catalysts.
The absence of a dominant sector theme this week suggests that the score improvements are company-specific rather than macro-driven. That's a higher-quality signal. Macro tailwinds lift all boats and obscure individual business quality; fundamental improvements that occur without a sector tailwind tend to be more durable.
None of this week's five names are in energy, industrials, or consumer — three sectors that have seen elevated score volatility year-to-date due to tariff uncertainty and commodity price movements.
Build Your Own Watchlist
These five stocks were selected based on the largest positive score changes this week. The methodology is transparent and consistent — the same filter runs every week across the full small-cap universe tracked by SmallCap Scanner.
You can replicate this approach using our screener: filter by score change over the past 7 days, sort descending, and review the top movers against the individual metric changes that drove each score. The screener allows you to layer additional filters — sector, minimum cash runway, profitability stage — so you can focus on the subset of movers that match your investment criteria.
The key discipline is consistency. Checking weekly for score movements — rather than reacting to price action — helps identify emerging opportunities before they show up in charts. Fundamental shifts precede price shifts in most cases. The lag can be weeks or quarters, but the direction of causality tends to hold.
See how SmallCap Scanner works for a complete walkthrough of the scoring model, data sources, and update cadence.
This article is for informational purposes only and does not constitute financial advice. Score changes reflect updated fundamental data and do not predict future stock performance. Always conduct your own research before making investment decisions.